Literature DB >> 29655276

Is sensitization to pig antigens detrimental to subsequent allotransplantation?

Qi Li1,2, Hidetaka Hara1, Zhongqiang Zhang3,4, Michael E Breimer5, Yi Wang2, David K C Cooper1.   

Abstract

An important question in xenotransplantation is whether an allotransplant can safely be carried out in a patient who has become sensitized to a pig xenograft. To answer this question, we have searched the literature. We primarily limited our review to the clinically relevant pig-to-non-human primate (NHP) model and found five studies that explored this topic. No NHP that had received a pig graft developed antibodies to alloantigens, and in vitro studies indicated no increased humoral and/or cellular alloreactivity. We carried out a small in vitro study ourselves that confirmed this conclusion. There have been three experiments in which patients undergoing dialysis were exposed to wild-type pig kidneys and three clinical studies related to bridging a patient in hepatic failure to liver allotransplantation. Despite the development of anti-pig antibodies, all subsequent organ (kidney or liver) allografts were successful (except possibly in one case). In addition, pig fetal islets were transplanted into patients with kidney allografts; there was no increase in panel-reactive alloantibodies and the kidney grafts continued to function satisfactorily. In conclusion, the limited data suggest that, after sensitization to pig antigens, there is no evidence of antibody-mediated or accelerated cellular rejection of a subsequent allograft.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antibodies, cross-reacting; clinical trial; immune response, human; non-human primate; pig; sensitization; xenotransplantation

Mesh:

Substances:

Year:  2018        PMID: 29655276      PMCID: PMC6005721          DOI: 10.1111/xen.12393

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  37 in total

1.  Interaction of anti-HLA antibodies with pig xenoantigens.

Authors:  N Barreau; Y Godfrin; J F Bouhours; J D Bignon; G Karam; E Leteissier; A Moreau; J Dantal; S Menoret; I Anegon; B M Imbert; S Brouard; J P Soulillou; G Blancho
Journal:  Transplantation       Date:  2000-01-15       Impact factor: 4.939

2.  Extracorporeal ("ex vivo") connection of pig kidneys to humans. II. The anti-pig antibody response.

Authors:  L Rydberg; S Björck; E Hallberg; S Magnusson; S Sumitran; B E Samuelsson; V Strokan; C T Svalander; M E Breimer
Journal:  Xenotransplantation       Date:  1996-11       Impact factor: 3.907

Review 3.  Current status of the swine leukocyte antigen complex.

Authors:  J K Lunney
Journal:  Vet Immunol Immunopathol       Date:  1994-10       Impact factor: 2.046

4.  Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation.

Authors:  R S Chari; B H Collins; J C Magee; J M DiMaio; A D Kirk; R C Harland; R L McCann; J L Platt; W C Meyers
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

5.  Organ transplantation between widely disparate species.

Authors:  R Y Calne
Journal:  Transplant Proc       Date:  1970-12       Impact factor: 1.066

6.  Allosensitization does not increase the risk of xenoreactivity to alpha1,3-galactosyltransferase gene-knockout miniature swine in patients on transplantation waiting lists.

Authors:  Banny S Wong; Kazuhiko Yamada; Masayoshi Okumi; Joshua Weiner; Patricia E O'Malley; Yau-Lin Tseng; Frank J M F Dor; David K C Cooper; Susan L Saidman; Adam Griesemer; David H Sachs
Journal:  Transplantation       Date:  2006-08-15       Impact factor: 4.939

7.  OPTN/SRTR 2015 Annual Data Report: Kidney.

Authors:  A Hart; J M Smith; M A Skeans; S K Gustafson; D E Stewart; W S Cherikh; J L Wainright; A Kucheryavaya; M Woodbury; J J Snyder; B L Kasiske; A K Israni
Journal:  Am J Transplant       Date:  2017-01       Impact factor: 8.086

8.  Transplantation of porcine fetal pancreas to diabetic patients.

Authors:  C G Groth; O Korsgren; A Tibell; J Tollemar; E Möller; J Bolinder; J Ostman; F P Reinholt; C Hellerström; A Andersson
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

9.  Extracorporeal ("ex vivo") connection of pig kidneys to humans. I. Clinical data and studies of platelet destruction.

Authors:  M E Breimer; S Björck; C T Svalander; A Bengtsson; L Rydberg; K Lie-Karlsen; P O Attman; M Aurell; B E Samuelsson
Journal:  Xenotransplantation       Date:  1996-11       Impact factor: 3.907

10.  HLA antibodies present in the sera of sensitized patients awaiting renal transplant are also reactive to swine leukocyte antigens.

Authors:  B Naziruddin; S Durriya; D Phelan; B F Duffy; B Olack; D Smith; T Howard; T Mohanakumar
Journal:  Transplantation       Date:  1998-10-27       Impact factor: 4.939

View more
  10 in total

Review 1.  A review of pig liver xenotransplantation: Current problems and recent progress.

Authors:  Xuan Zhang; Xiao Li; Zhaoxu Yang; Kaishan Tao; Quancheng Wang; Bin Dai; Shibin Qu; Wei Peng; Hong Zhang; David K C Cooper; Kefeng Dou
Journal:  Xenotransplantation       Date:  2019-02-15       Impact factor: 3.907

Review 2.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

Review 3.  The 2021 IXA Keith Reemtsma Lecture: Moving xenotransplantation to the clinic.

Authors:  David K C Cooper
Journal:  Xenotransplantation       Date:  2021-12-29       Impact factor: 3.907

4.  Initial experimental experience of triple-knockout pig red blood cells as potential sources for transfusion in alloimmunized patients with sickle cell disease.

Authors:  Takayuki Yamamoto; Mohamed H Bikhet; Marisa B Marques; Huy Q Nguyen; Yehua Cui; Mariyam Javed; Syed Sikandar Raza; David Ayares; Hayato Iwase; David K C Cooper; Hidetaka Hara
Journal:  Transfusion       Date:  2021-09-22       Impact factor: 3.157

5.  Xenogeneic cross-circulation for extracorporeal recovery of injured human lungs.

Authors:  Ahmed E Hozain; John D O'Neill; Matthew Bacchetta; Gordana Vunjak-Novakovic; Meghan R Pinezich; Yuliya Tipograf; Rachel Donocoff; Katherine M Cunningham; Andrew Tumen; Kenmond Fung; Rei Ukita; Michael T Simpson; Jonathan A Reimer; Edward C Ruiz; Dawn Queen; John W Stokes; Nancy L Cardwell; Jennifer Talackine; Jinho Kim; Hans-Willem Snoeck; Ya-Wen Chen; Alexander Romanov; Charles C Marboe; Adam D Griesemer; Brandon A Guenthart
Journal:  Nat Med       Date:  2020-07-13       Impact factor: 87.241

Review 6.  Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.

Authors:  Abhijit Jagdale; David K C Cooper; Hayato Iwase; Robert S Gaston
Journal:  Xenotransplantation       Date:  2018-11-20       Impact factor: 3.907

Review 7.  Clinical Pig Kidney Xenotransplantation: How Close Are We?

Authors:  David K C Cooper; Hidetaka Hara; Hayato Iwase; Takayuki Yamamoto; Abhijit Jagdale; Vineeta Kumar; Roslyn Bernstein Mannon; Michael J Hanaway; Douglas J Anderson; Devin E Eckhoff
Journal:  J Am Soc Nephrol       Date:  2019-12-02       Impact factor: 10.121

Review 8.  Aspects of histocompatibility testing in xenotransplantation.

Authors:  Joseph M Ladowski; Julie Houp; Vera Hauptfeld-Dolejsek; Mariyam Javed; Hidetaka Hara; David K C Cooper
Journal:  Transpl Immunol       Date:  2021-05-17       Impact factor: 2.032

9.  Pig-to-human heart transplantation: Who goes first?

Authors:  Richard N Pierson; Lars Burdorf; Joren C Madsen; Gregory D Lewis; David A D'Alessandro
Journal:  Am J Transplant       Date:  2020-05-25       Impact factor: 9.369

10.  Serum Antibody Binding and Cytotoxicity to Pig Cells in Chinese Subjects: Relevance to Clinical Renal Xenotransplantation.

Authors:  Tao Li; Hao Feng; Jiaxiang Du; Qiangbing Xia; David K C Cooper; Hongtao Jiang; Songzhe He; Dengke Pan; Gang Chen; Yi Wang
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.